Abstract Number: PB0971
Meeting: ISTH 2021 Congress
Background: We previously reported that platelets markedly accumulated in hepatocellular carcinoma (HCC) and they were activated during tumor progression. Platelets are able to internalize extracellular substances, which are then released upon activation.
Aims: We hypothesized that autologous platelets could be a potential drug carrier for cancer therapy. We propose a unique HCC therapy using autologous platelets as a drug carrier.
Methods: We induced HCC in rats according to the Solt & Farber protocol. Then, we collected the blood from the tail vein of the tumor-bearing rats. Platelets were isolated and incubated with sorafenib in vitro. The rats were divided into 4 experimental groups: saline, sorafenib, platelets, and platelets incubated with sorafenib (Sora-PLT); saline, sorafenib, platelets and Sora-Plt were injected via the tail vein of the host rats.
Results: Although platelets did not exert any effects, Sora-Plt treatment induced significant regression of the tumors. The tumor-suppressing effect of Sora-Plt was superior to that induced by sorafenib.
Conclusions: Our results indicate that the use of autologous platelets containing anti-cancer drugs could be a novel therapeutic strategy for HCC.
To cite this abstract in AMA style:Tanaka H, Horioka K. A Novel Therapeutic Strategy for Hepatocellular Carcinoma Based on the Tumor-platelet Interaction [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/a-novel-therapeutic-strategy-for-hepatocellular-carcinoma-based-on-the-tumor-platelet-interaction/. Accessed December 7, 2021.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/a-novel-therapeutic-strategy-for-hepatocellular-carcinoma-based-on-the-tumor-platelet-interaction/